June 2012CURRICULUM VITAE

Name: Matthew Martin Ames, Ph.D.

Address: P.O. Box 9717778 E. North Shore LaneBayview, Idaho 83803cucreek@yahoo.com208 683-0566

Work Address: Department of Molecular Pharmacology and Experimental Therapeutics Mayo Clinic & Foundation Rochester, Minnesota 55905 ames.matthew@mayo.edu

Date and Place of Birth: December 17, 1947; Richland, Washington

Citizenship: United States

Marital Status: Married

Education:1961 – 1966 Mead High School, Spokane, Washington (Class Salutatorian)1966 – 1970 B.A., Chemistry, Whitman College, Walla Walla, Washington, 1971 – 1975 Ph.D., Pharmaceutical Chemistry, University of California, San Francisco,

Research Advisor: Neal Castagnoli, Jr., Ph.D.1975 – 1977 Staff Research Associate: Pharmacology Research Associate Training

Program (PRAT) Fellowship, Section on Biochemical Pharmacology, Hypertension-Endocrine Branch, NHLBI, NIH, Bethesda, Maryland; Dr. Walter Lovenberg, Preceptor

Positions:

1970 – 1971 Staff Research Assistant, Chemistry Department, Pomona College, Claremont, California

1973 – 1975 Research Assistant in Mass Spectrometry Laboratory, Department of Pharmaceutical Chemistry, University of California, San Francisco, California

1977 – 1979 Instructor of Pharmacology, Mayo Medical School and Mayo Graduate School,

1977 – 1978 Senior Research Associate, Division of Developmental Oncology Research, Department of Oncology, Mayo Clinic andFoundation

1978 – 1980 Associate Consultant, Division of Developmental Oncology Research, Department of Oncology, Mayo Clinic and Foundation

1979 – 1981 Assistant Professor of Pharmacology, Mayo Medical School and Mayo Graduate School

1980 – 2012 Consultant, Division of Developmental Oncology Research, Department of Oncology, Mayo Clinic and Foundation

2 M.M. Ames, Ph.D.1981 – 1989 Associate Professor of Pharmacology, Mayo Medical School and Mayo

Graduate School1987 – 2003 Chair, Division of Developmental Oncology Research, Department of

Oncology, Mayo Clinic and Foundation1989 – 2012 Professor of Pharmacology, Mayo Medical School and Mayo Graduate

School1993 – 1999 Director for Research, Mayo Clinic and Foundation, Rochester2003 – 2012 Chair, Department of Molecular Pharmacology and Experimental

Therapeutics, Mayo Medical School and Mayo Graduate School2003 – 2012 Associate Medical Director of Development-Cancer, Mayo Clinic and

Foundation2007 – 2012 Sandra J. Schulze Endowed Professor, Mayo Graduate School and

Medical School2011 – 2012 Senior Associate Medical Director of Development, Mayo Clinic and

Foundation2012- Emeritus Faculty and Staff, Mayo Clinic and Foundation2012- Part-time Consultant, Department of Development, Mayo Clinic and

Foundation2012- Research Collaborator, Departments of Molecular Pharmacology and

Experimental Therapeutics and Oncology, Mayo Clinic and Foundation

Memberships   in   Scientific   Societies :

American Association for the Advancement of ScienceAmerican Society for Pharmacology and Experimental Therapeutics American Association of Cancer ResearchAmerican Society for Pharmacology and Therapeutics

Extramural   Activities :

Study Sections/Committees1986 – 1989 Member, NIH Study Section, Developental Therapeutics1984 – 2000 Vice Chair, New Agents and Pharmacology Steering Committee,

Childrens Cancer Group1990 – 1993 Member, Veterans Administration Oncology Merit Review Board1998 – 2000 Vice Chair, New Agents Strategy Group, Childrens Cancer Group 2001 – 2012 Member, Developmental Therapeutics Committee, Children’s Oncology

Group2001 – 2012 Chair, Pharmacology Subcommittee, Developmental Therapeutics

Committee, Children’s Oncology Group2001 – 2012 Member, Executive Subcommittee, Developmental Therapeutics

Committee, Children’s Oncology Group2004 Ad Hoc Member, Drug Discovery and Molecular Pharmacology Study

Section, National Institutes of Health2004 – 2007 Member, Program Project Subcommittee D, National Cancer Institute2005 – 2011 Member, Ralph C. Wilson Medical Researh Foundation Advisory Board2008 Chair, Ralph C. Wilson Medical Research Foundation Advisory Board

Site   Visits/Ad - Hoc   Committee   Assignments :

3 M.M. Ames, Ph.D.

Extramural Site Visit Team, Laboratory of Medicinal Chemistry and Pharmacology, Division of Cancer Treatment, National Cancer Institute, November, 1983

Extramural Site Visit Team, Pediatric Branch, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, October, 1984

National Institutes of Health General Clinical Research Centers Program Site Visit Team, University of Alabama, December, 1985

Chair, Ad Hoc Developmental Therapeutics Contract Review Committee Meeting, National Cancer Institute, April and November, 1986

National Cancer Institute Program Project Site Visit Team, M.D. Anderson Hospital and Tumor Institute, 1988

Ad Hoc Experimental Therapeutics - Two (ET-2) Study Section, National Institutes of Health, 1989

National Cancer Institute Program Project Site Visit Team, Southern Research Institute, 1989National Cancer Institute Program Project Site Visit Team, University of Southern California,

1990Extramural Site Visit Team, Laboratory of Drug Discovery, Research and Development,

Division of Cancer Treatment, National Cancer Institute, Frederick, MD, 1991Chair, Extramural Site Visit Team, AIDS Clinical Trials Group, Rockville, MD, 1995National Cancer Institute Site Visit Team, University of California at San Francisco, Cancer

Research Institute, San Francisco, CA, 1996National Cancer Institute Cancer Center Review Site Visit Team, Massey Cancer Center,

Richmond, VA, 1998National Cancer Institute Center Review Site Visit Team, Cancer Institute of New Jersey, New

Brunswick, NJ, 1999National Cancer Institute Center Review Site Visit Team, University of Colorado Cancer Center,

Denver, CO, 2000.Extramural Site Visit Team, Laboratory of Medicinal Chemistry, National Cancer Institute,

Frederick, MD, 2001Member, Extramural Site Visit Team, Pediatric Oncology Branch, National Cancer Institute,

Bethesda, MD, October 23-October 25, 2006

Other

American Association for Cancer Research Program Committee (Pharmacology and Therapeutics), 1998

American Association for Cancer Research G.H.A. Clowes Memorial Award Selection Committee, 1999.

Governmental Affairs Committee, American Society for Clinical Pharmacology and Therapeutics, 2004-2007

American Association for Cancer Research Program Committee (Clinical Pharmacology and Phase I Clinical Trials, Pharmacology, Pharmacogenetics and Pharmacogenomics), 2004

Honors and Other Special Scientific Recognition: Honors at Entrance, Whitman College, 1966Patent Fund Award, University of California, 1974Pharmacology Research Associate Trainee (PRAT) Fellowship, NIH, 1975 – 1977National Cancer Research Fellow, Ladies Auxiliary, Veterans of Foreign Wars, 1977National Cancer Institute Research Career Development Award 1981 Teacher of the Year, Oncology, Pharmacology, Mayo Medical School, 1987

4 M.M. Ames, Ph.D.Whitney and Elizabeth MacMillan Scholar, 1996.First Annual Mayo Research Symposium, Best Poster, Pharmacology, 1999.Teacher of the Year, Molecular Pharmacology and Experimental Therapeutics, Mayo Graduate

School, 2000Sandra J. Schulze Endowed, Named Professorship

Manuscript Reviewer

Analytical BiochemistryBiochemical PharmacologyCancerCancer Chemotherapy and PharmacologyCancer ResearchClinical Cancer ResearchClinical Pharmacology and TherapeuticsDrug Metabolism and DispositionJournal of Clinical OncologyJournal of ChromatographyJournal of Medicinal ChemistryLeukemiaMayo Clinic ProceedingsMolecular PharmacologyPharmacogenomics

Editorial Boards:

Editorial Board, Journal of Medicinal Chemistry (1987-1996)Editorial Board, Analytical Biochemistry (1983-1995)Editorial Board, Clinical Pharmacology and Therapeutics (1991-2003)

Administration Activities:

Research Research Committee, 1987-1999; 2010-2012Fiscal Subcommittee, 1989-1992Chair, Fiscal Subcommittee, 1991-1992Chair, Research Committee, 1993-1999Director for Research, 1993-1999

Institutional Board-Appointed CommitteesContinuous Improvement Council, 1993-1995Chair, Distinguished Investigator Selection Committee, 1993-1999Strategic Alliances Committee, 1993-2000Diversity Committee, 1993-1996Foundation Research Liaison Committee, 1993-1997Personnel Committee, 1993-2000Development Policy Committee, 1994-2000Finance Committee, 1995-1999Annual Planning and Strategic Work Group, 1995-1999Mayo Regional Healthcare Network Group, 1996-1998

5 M.M. Ames, Ph.D.Administrative Committee, 1997-2000Medical Industry Relations Committee, 1999-2011Medical Industry Relations Committee, Executive Subcommittee, 2001-2011

Medical Industry Relations Committee, Vice-Chair, 2008-2011Embryonic Stem Cell Policy Task Force, 2001Director for Research Nominating Task Force, 2004Mayo Comprehensive Cancer Center Director Search Committee, 2005Endowed Professorship Selection Committee, 2007-2012Chair, Stem Cell Research Task Force, 2007

Department of OncologyOncology Research Committee, 1987-1993Oncology Education Committee, 1987-1992Executive Committee, 1987-2003

Department of Molecular Pharmacology and Experimental TherapeuticsEducation Committee, 2006-2012Graduate Program Director, 1999-2003Chair, 2003-2012

NCI Comprehensive Cancer CenterMember, 1976-2012Developmental Therapeutics Program, 1977-2012Leader, Developmental Therapeutics Program, 1987-2004Co-Leader, Developmental Therapeutics Program, 2005-2012Director, Pharmacology Shared Resource Facility, 1987-2012Executive Committee, 1995-2012

Mayo Graduate School:Course Director, Readings in Pharmacology Graduate Course (Phar 8800), 1986-1993,

2000-2003Lecturer, Drug Metabolism, Carcinogenesis and Pharmacogenomics (Phar 8805),

1978-2012Lecturer, Tumor Biology (TB 8000), 1983-2003 Lecturer, Toxicology Graduate Course (Phar 8810), 1988-1992Lecturer, Cellular Pharmacology Course (Phar 8811), 1996-2003Faculty Member, Neuroscience Program, 1999-2007Member, Graduate School Education Committee, 1999-2003 Principal Investigator, NIH Pharmacology Predoctoral Training Grant, 2005-2010

Mayo Medical School:Lecturer, Pharmacology and Therapeutics (MMS II), 1977-2012

Mayo M.D./Ph.D. ProgramM.D./Ph.D. Program Committee, 2002-2004M.D./Ph.D. Program Executive Committee, 2002-2004

Patents:

6 M.M. Ames, Ph.D.

No. 4,963,655: October 16, 1990, Boron Analogs of Amino Acid/Peptide Protease Inhibitors, David H. Kinder and Matthew M. Ames

No. 5,004,593: April 2, 1991, Hexamethylmelamine Formulation Exhibiting Reduced Neurotoxicity, Matthew M. Ames and John S. Kovach

No. 5,106,948: April 21, 1992, Cytotoxic Boronic Acid Peptide Analogs

No. 5,159,060: October 27, 1992, Cytotoxic Boronic Acid Peptide Analogs

INVITED   SPEAKER

University of Washington, Seattle, "Analytical Methods in the Determination of Chemotherapeutic Agents in Biological Fluids," June 29 and 30, 1978.

Minnesota Chromatography Forum, High Performance Liquid Chromatography Workshop, Bloomington, Minnesota, "Studies With Anti-Cancer Agents," March 6, 1978.

University of North Carolina, Automated Biochemical Systems Laboratory, Chapel Hill, North Carolina, "Effects of Phosphorylation and End-Product Inhibition on the Activation of Tyrosine Hydroxylase," May 15, 1978.

Marshall University, Department of Pharmacology, Huntington, West Virginia, "Activation and End Product Inhibition of Tyrosine Hydroxylase in Rat Brain," May 12, 1978.

Mayo Clinic, Pharmacology Seminar Series, Rochester, Minnesota, "Regulation and Activation of Tyrosine Hydroxylase in Rat Brain," January 13, 1978.

Mayo Clinic, Experimental Pathology Seminars, Rochester, Minnesota, "Quantitative Analysis and Pharmacology of Chemotherapeutic Agents in Animals and Man," January 9, 1979.

Mayo Clinic, The Laboratory Society, Rochester, Minnesota, "Cancer Pharmacology Laboratory," September 14, 1979.

University of Minnesota, Medicinal Chemistry Department, Minneapolis, Minnesota, "Pharmacology of Phase I Anticancer Agents." October 2, 1979.

Riker Laboratories, Inc. (3M Company), "Disposition and Metabolism Studies on Two New Anticancer Candidates: Indicine N-Oxide and Pentamethylmelamine," November 26, 1979.

Mayo Clinic, Therapeutic Drug Monitoring Workshop, Rochester, Minnesota, "Antineoplastic Drugs," October 24, 1980.

Mayo Clinic, Mayo Comprehensive Cancer Center, Employee Education Program, Rochester, Minnesota, "Treatment of Chemotherapy-Induced Nausea and Vomiting," January 25, 1982.

Whitman College, Sigma XI, The Scientific Research Society of North America, Walla Walla, Washington, "Pharmacology of Methylmelamine Antitumor Agents," September 20, 1982.

7 M.M. Ames, Ph.D.Memorial Sloan-Kettering Cancer Center, New York, New York, "The Mechanism of Action of Methylmelamine Antitumor Agents," September 14, 1983.

Mayo Clinic, Mayo Comprehensive Cancer Center, Cancer Nursing Update, Rochester, Minnesota, "Discussion of Development of Chemotherapeutic Drugs: Pharmacology, Interactions, Side Effects, and Nursing Implications for Care of the Cancer Patient," April 22, 1983.

University of Wisconsin, Wisconsin Clinical Cancer Center, Madison, Wisconsin, "Preclinical and Clinical Pharmacology Studies of Two Triazene Anticancer Agents: Teroxirone and Hexamethylmelamine," June 28, 1985.

University of Colorado School of Medicine, Boulder, Colorado, "Preclinical and Clinical Pharmacological Studies With Triazine Anti-Tumor Agents," May 31, 1986.

National Cancer Institute, Contractors Workshop, Bethesda, Maryland, "Preclinical Pharmacology of the Experimental Antitumor Agent Diazohydroxide," October 6, 1987.

University of Southern California, Comprehensive Cancer Center, Pasadena, California, "Development of Anticancer Agents: Integration of Preclinical and Clinical Pharmacology," November 9, 1987.

Mayo Clinic, Clinician-Investigator Seminars, Rochester, Minnesota, "Development of Mechanism Based Inhibitors of de novo Pyrimidine Biosynthetic and Protease Enzymes as Potential Anticancer Agents," March 8, 1988.

Wayne State University, School of Medicine, Department of Pharmacology, Detroit, Michigan, "Novel Antitumor Agents: Transition State Protease Inhibitors," April 25, 1988.

National Cancer Institute of Canada, Ontario Cancer Foundation, Kingston, Ontario, "Preclinical and Clinical Pharmacology in Cancer Drug Development," September 15, 1988.

Queen's University School of Medicine, Kingston, Ontario, "Transition-State Inhibitors of Serine Proteases," September 15, 1988.

Mayo Clinic, Rochester, Minnesota, Laboratory of Medicine Continuing Education Series, "Anticancer Agents: New Drug Development," October 26, 1988.

Symposium: Idarubicin: New Prospects for Patients with Acute Leukemia, sponsored by Montefiore Medical Center in conjunction with American Society of Hematology, San Antonio, Texas, "Pharmacokinetics of Idarubicin in Pediatric Patients with Acute Leukemia," December 2, 1988.

Mayo Clinic Research Society, Rochester, Minnesota, "Design, Evaluation and Characterization of Experimental Antineoplastic Agents," September 12, 1989.

University of Minnesota, School of Pharmacy, Department of Medicinal Chemistry, Minneapolis, Minnesota, "Mechanism-Based Enzyme Inhibitors as Potential Anticancer Agents," April 17, 1990.

8 M.M. Ames, Ph.D.Childrens Cancer Study Group Affiliates Meeting, Mayo Clinic, Rochester, Minnesota, "Pediatric Pharmacokinetic and Basic Laboratory Studies With Idarubicin and Idarubicinol", October 19, 1990.

Keystone Symposia, Anthracyclines: Recent Progress in Pharmacology, Big Sky, Montana, "Pharmacology and Pharmacokinetics of Idarubicin," April 10, 1991.

Mayo Clinic Laboratory Society, Role of Basic and Clinical Pharmacology in the Development of New Anticancer Agents, May 10, 1991.

5th International Symposium on Therapy of Acute Leukemias, Rome, Italy, "Biochemical and Clinical Pharmacology of Idarubicin," November 1-6, 1991.

Department of Pediatrics, M.D. Anderson Cancer Center, Houston, TX, "Novel Biochemical and Pharmacologic Aspects of the Antileukemic Agent Idarubicin", October 18, 1992.

Department of Pharmacology, M.D. Anderson Cancer Center, Houston, TX, "Boronic Acid Analog Mechanism-Based Serine Protease Inhibitor as Potential Antitumor Agents," October 18, 1992.

VIth International Conference on Malignant Lymphoma, Lugano, Switzerland, "Idarubicin: Basic and Clinical Pharmacology," June 4, 1996.

Mayo Cancer Center, Works in Progress, Rochester, MN, "Serine Proteases: Targets for Chemotherapeutic Agents," September 27, 1996.

Oncology Grand Rounds, Mayo Clinic, Rochester, MN, "The Mayo Clinic Experience with Dolastatin-10: A Paradigm for Translational Therapeutic Research," January 10, 1997.

Advanced Management for Healthcare Executive Program, Carlson School of Management, University of Minnesota and Mayo Foundation, Rochester, MN, “A Window Into Mayo-Research,” March 31, 1998.

Mayo Clinic, Molecular Neurosciences Seminar, “Serine Proteases: Targets for Cancer Chemotherapeutic Agents (Maybe even in neuroendocrine tumors),” May 5, 1998.

Doctor Mayos Society Annual Meeting, Rochester, MN, “Mayo Research – A Look to the Future,” August 29, 1998.

4th Annual Montana Neurosurgery Symposium, Bigfork, MT, “Novel Therapies for Brain Tumors,” September 2, 1998.

Developmental Therapeutics Program, National Cancer Institute, Frederick, MD, “Aminoflavone (NSC 686288): Microsomal Metabolism: A Mechanism of Action?” August 11, 1999.

Mayo Laboratory Society, Rochester, MN, "Aminoflavone: A Potent Antitumor Agent with a Novel Mechanism of Action,” November 12, 1999.

9 M.M. Ames, Ph.D.6th Annual Montana Neurosurgery Symposium, Bozeman, MT, Aminoflavone: A Potent Antitumor Agent with a Novel Mechanism of Action,”, August 29, 2000.

Developmental Therapeutics Program, National Cancer Institute, Frederick, MD, “Aminoflavone: Does Cytochrome P450 1A1/1A2 Biotransformation Mediate Growth Inhibition of Human Tumor Cells in Culture?”, January 24, 2001.

9th Annual Progress in Clinical Pathology Meeting, University of Texas Southwestern, Dallas Texas, "A New Paradigm: Pharmacogenetics and Pharmacogenomics," April 12, 2002.

North Central Cancer Treatment Group, Pharmacogenetics & Pharmacogenomics: A few Basics, Two Paradigms, and Several Applications, Mayo Clinic, Rochester, Minnesota, "Pharmacogenomics & Oncology: A New Paradigm", October 10, 2002.

Verto Institute Neuroendocrine Research Meeting, Princeton NJ, "Biology Studies of Indolent and Aggressive Carcinoid Tumors", November 12, 2002.

Department of Pharmacology, University of Alabama School of Medicine, Birmingham, Alabama, “Aminoflavone: A Novel Mechanism of Action Involving CYP1A1/1A2 Induction in Tumor Cells, June 6, 2003.

Mayo Health Summit, “Targeted Cancer Therapies” and “The Right Drug at the Right Dose for Every Patient”, Venice, Italy, June 20-25, 2006.

Department of Biomedical Sciences, University of Montana, Missoula, Montana, “Aminoflavone: A Molecularly-targeted Anticancer Agent with a Novel Mechanism of Action, November 17, 2006.

First Annual Schulze Symposium on Novel Therapeutics-Using Genomics as a Guide to Cancer Therapeutics, Mayo Comprehensive Cancer Center, Rochester, Minneosta, “UGT1A1 Genetic Variance Determines Maximally Tolerated Doses and Pharmacokinetics of Irinotecan-based Chemotherapy”, September 17, 2007.

Second Annual Schulze Symposium on Novel Therapeutics: Novel Therapeutic Targets for the Treatment of Cancer, Mayo Comprehensive Cancer Center, Rochester, Minnesota, “2-Aminoflavone: A Novel DNA Damaging Agent Active in Breast Cancer Models”, November 7, 2008.

University of Montana, Missoula, Montana, “The Critical Role of Drug-Metabolizing Enzyme Genotypes in Irinotecan and Tamoxifen Cancer Therapy”, December 4, 2008

St. Patrick’s Hospital, Missoula, Montana. “Individualized Medicine: The Right Drug at the Right Dose for Every Patient”, December 5, 2008

Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD, “Endoxifen as a Novel Hormonal Therapy for Breast Cancer” (jointly with Dr. Matthew P. Goetz), May, 2009

Two Days with Mayo Clinic in Northern California, “Cancer Therapy: The Right Drug at the Right Dose for Every patient”, Napa, California, October 14, 2010.

10 M.M. Ames, Ph.D.Research Interests

Molecular mechanisms of anticancer agent activity and resistancePreclinical pharmacology of antitumor agentsClinical pharmacology of antitumor agents in adult and pediatric cancer patientsPharmacogenomics of drug response genes Aminoflavone and other antitumor agents requiring tumor cell metabolic activationThe biology and therapy of neuroendocrine tumorsPharmacogenetics of tamoxifen and development of endoxifen as a novel agent for the treatment of estrogen receptor positive (ER+) breast cancer

11 M.M. Ames, Ph.D.BIBLIOGRAPHY

Peer-Reviewed Articles

1. Ames MM Castagnoli N Jr. The synthesis of 13C-enriched alpha-methyldopa. J Labeled Compds 1974; 10:195-205.

2. Smith RN, Hansch C, Ames MM. Selection of a reference partitioning system for drug design work. J Pharm Sci 1975 Apr; 64(6):599-606.

3. Ames MM, Nelson SD, Lovenberg W, Sasame HA. Metabolic activation of para-chloroamphetamine to a chemically reactive metabolite. Comm Psychopharmacol 1977; 1:455-460.

4. Ames MM, Melmon KL Castagnoli N Jr. Stereochemical course in vivo of alpha-methyldopa decarboxylation in rat brains. Biochem Pharmacol 1977; 26(9):1757-1762.

5. Gal J, Ames MM. Gas-chromatographic resolution of the enantiomers of 3-(3,4-dihydroxyphenyl)alanine and its a-methyl analog. Anal Biochem 1977; 83:266-273.

6. Lerner P, Ames MM, Lovenberg W. The effect of ethylene glycol bis(-aminoethyl ether)-N,N'-tetraacetic acid and calcium on tyrosine hydroxylase activity. Mol Pharmacol 1977; 13:44-49.

7. Lerner P, Hartman P, Ames MM, Lovenberg W. The role of reductants in the tyrosine hydroxylase reaction. Arch Biochem Biophys 1977; 182:164-170.

8. Sasame HA, Ames MM, Nelson SD. Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. Biochem. Biophys. Res. Commun 1977, 78(3):919-926.

9. Lovenberg W, Ames MM, Lerner P. Regulation of the tyrosine hydroxylase activity. Adv Biochem Psychopharmacol. 1977; 16:461-464

10. Ames MM, Lerner P, Lovenberg W. Tyrosine hydroxylase: activation by protein phosphorylation and end product inhibition. J Biol Chem 1978; 253:27-31.

11. Lerner P, Nose P, Ames MM, Lovenberg W. Modification of the tyrosine hydroxylase assay: increased enzyme activity in the presence of ascorbic acid. Neurochem Res 1978; 3:641-651.

12. Flora KP, Cradock JC, Ames MM. A simple method for the estimation of amygdalin in urine. Res Comm Chem Pathol Pharmacol 1978; 20:367-378.

13. Ames MM, Kovach JS, Flora KP. Initial pharmacologic studies of amygdalin (laetrile) in man. Res Comm Chem Pathol Pharmacol 1978; 22(1):175-185.

12 M.M. Ames, Ph.D.14. Ames MM, Powis G. Determination of indicine N-oxide and indicine in plasma and

urine by electron-capture gas-liquid chromatography. J Chromatogr 1978; 166:519-526.

15. Kovach JS, Ames MM, Sternad ML, O'Connell MJ. Phase I trial and assay of rubidazone (NSC-164011) in patients with advanced solid tumors. Cancer Res 1979; 39:823-828.

16. Ames MM, Powis G, Kuehn PW. Determination of pyrazoloimidazole in plasma and urine by gas-liquid chromatography using nitrogen-phosphorus detection. J Chromatogr 1979; 169:412-415.

17. Powis G, Ames MM. Determination of L-alanosine in plasma and urine by reversed-phase high-performance liquid chromatography of the Dns derivative. J Chromatogr 1979; 170:195-201.

18. Ames MM, Powis G. Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen-phosphorus gas-liquid chromatography. J Chromatogr 1979; 174:245-249.

19. Powis G, Ames MM, Kovach JS. Relationship of the reductive metabolism of indicine N-oxide to its antitumor activity. Res Comm Chem Pathol Pharmacol 1979; 24(3):559-569.

20. Powis G, Ames MM, Kovach JS. Metabolic conversion of indicine N-oxide to indicine in rabbits and humans. Cancer Res 1979; 39:3564-3570.

21. Kovach JS, Ames MM, Powis G, Moertel CG, Hahn RG, Creagan ET. Toxicity and pharmacokinetics of a pyrrolizidine alkaloid, indicine N-oxide, in humans. Cancer Res 1979; 39:4540-4544.

22. Ames MM, Powis G, Kovach JS, Eagan RT. Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. Cancer Res 1979; 39:5016-5021.

23. Powis G, Ames MM. Determination of 6-diazo-5-oxo-L-norleucine in plasma and urine by reversed-phase high-performance liquid chromatography of the dansyl derivative. J Chromatogr 1980; 181:95-99.

24. Lieber MM, Ames MM, Powis G, Kovach JS. Anticancer drug testing in vitro: use of an activating system with the human tumor stem cell assay. Life Sci 1981; 28:287-293.

25. Letendre L, Smithson WA, Gilchrist GS, Burgert EO Jr, Hoagland CH, Ames MM, Powis G, Kovach JS. Activity of indicine N-oxide in refractory acute leukemia. Cancer 1981; 47(3):437-441.

26. Moertel CG, Ames MM., Kovach JS, Moyer TP, Rubin JR, Tinker, JH. A pharmacologic and toxicological study of amygdalin. J Am Med Assoc. 1981; 245(6):591-594.

13 M.M. Ames, Ph.D.27. Ames MM, Moyer TP, Kovach JS, Moertel CG, Rubin J. Pharmacology of amygdalin

(laetrile) in cancer patients. Cancer Chemother Pharmacol 1981; 6:51-57.

28. Powis G, Ames MM, Kovach JS. Dose-dependent pharmacokinetics and cancer chemotherapy. A review. Cancer Chemother Pharmacol 1981; 6:1-9.

29. Ames MM, Sanders ME, Tiede WS. Metabolic activation of hexamethylmelamine and pentamethylmelamine by liver microsomal preparations. Life Sci 1981; 29:1591-1598.

30. Eagan RT, Ames MM, Powis G, Kovach JS. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol (NSC-132313). Cancer Treat Rep 1982; 66:283-287.

31. Ames MM, Frank SK. Stereochemical aspects of para-chloroamphetamine metabolism. Rabbit liver microsomal metabolism of RS, R(-), and S(+) para-chloroamphetamine. Biochem Pharmacol 1982; 31(1):5-9.

32. Ames MM, Kovach JS. Parenteral formulation of hexamethylmelamine potentially suitable for use in man. Cancer Treat Rep 1982; 66(7):1579-1581.

33. Ames, MM., Miser JS, Smithson WA, Coccia PF, Hughes CS, Davis DM. Pharmacokinetic study of indicine N-oxide in pediatric cancer patients. Cancer Chemother Pharmacol 1982; 10(1):43-46.

34. Ames MM, Sanders ME, Tiede WS. Role of N-methylol-pentamethylmelamine in the metabolic activation of hexamethylmelamine. Cancer Res 1983; 43:500-504.

35. Agrez MV, Ames MM, Lieber MM. In vitro chemotherapy sensitivity patterns of human colon carcinoma continuous cell lines. J Surg Oncol 1983; 24:79-82.

36. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharm 1983; 24:471-478.

37. Miller KJ, Gal J, Ames MM. High-performance liquid chromatographic resolution of enantiomers of l-phenyl-2-aminopropanes (amphetamines) with four chiral reagents. J Chromatogr 1984; 307:335-342.

38. Sanders ME, Ames MM. Synthesis of N-methylolpentamethyl-melamine (ring 14C), a cytotoxic-alkylating metabolite of hexamethylmelamine. J Lab Comp Radiopharmaceut 1984; 21(10):893-898.

39. Frytak S, Eagan RT, Ames MM, Creagan ET, Nichols WC. Phase I study of diaziquone. Cancer Treat Rep 1984; 68:975-978.

40. Ames MM, Kovach JS Rubin J. Pharmacologic characterization of teroxirone, a triepoxide antitumor agent, in rats, rabbits, and humans. Cancer Res 1984; 44:4151-4156.

14 M.M. Ames, Ph.D.41. Agrez MV, Ames MM, Lieber MM, Tyce GM. The Presence of serotonin in animal sera

used in cell culture. Biogenic Amines 1984;1:223-228.

42. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin c versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Eng J Med 1985; 312:137-141.

43. Miller KJ, McGovern R, Ames MM. Effect of hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines. Cancer Chemother Pharmacol 1985; 15:49-53.

44. Ames MM, Miller KJ, Moertel DM. High-performance liquid chromatographic assay and preclinical pharmacological studies of pibenzimol (bisbenzimidazole). J Chromatogr, Biomed Appl 1985; 341:89-96.

45. Sanders ME, Ames MM. Acylhydroperoxide oxidations of the anticancer agent hexamethylmelamine. Tetrahedron Lett 1985; 26:5247.

46. Ames MM, Selassie CD, Woodson LC, Van Loon JA, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates. J Med Chem 1986; 29(3):354-358.

47. Miller KJ, Anderholm DC, Ames MM. Metabolic activation of the serotonergic neurotoxin para-chloroamphetamine to chemically reactive intermediates by hepatic and brain microsomal preparations. Biochem Pharmacol 1986; 35(10):1737-1742.

48. Frank SK, Mathiesen DA, Whitfield LR, Ames MM. High-performance liquid chromatographic assay for the experimental anticancer agent oxantrazole. J Chromatogr, Biomed Appl 1987; 419:225-232.

49. Rubin J, Kovach JS, Ames MM, Moertel CG, Creagan, ET, O'Connell, MJ. Phase I study of two schedules of teroxirone. Cancer Treat Rep 1987; 71(5):489-492 .

50. Campbell NRC, Van Loon JA, Sundaram RS, Ames MM, Hansch C, Weinshilboum R. Human and rat liver phenol sulfotransferase: structure-activity relationships for phenolic substrates. Mol Pharm 1987; 32:813-819.

51. Kinder DH, Ames MM. Synthesis of 2-amino-3-boronopropionic acid: a boron containing analog of aspartic acid. J Org Chem 1987; 52(12):2452-2454.

52. Kovach JS, Richardson RL. and Ames MM. Cisplatinum: New clinical applications. Excerpta Medica, Ltd 1987; 2:298-307.

53. Rubin J, Ames MM, Schutt AJ, Fitch TR, Cole TL, Bowie EJW, Kovach JS. Flavone-8-acetic acid, an anticancer drug, inhibits von willebrand factor mediated platelet function. Lancet 1988; 2:1081-1082.

15 M.M. Ames, Ph.D.54. Frank SK, Mathiesen DA, Szurszewski M, Kuffel MJ, Ames MM. Preclinical

pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174). Cancer Chemother Pharmacol 1989; 23(4):213-218.

55. Ames MM, Mathiesen DA. High-performance liquid chromatographic assay and preclinical pharmacologic studies with the experimental antitumor agent batracylin. J Chromatogr, Biomed.Appl 1989; 491(2):488-494.

56. Ames MM, Richardson RL, Kovach JS, Moertel CG, O'Connell MJ. Phase I and clinical pharmacologic evaluation of a parenteral hexamethylmelamine formulation. Cancer Res 1990; 50:206-210 (1990).

57. Kinder DH, Frank SK, Ames MM. Analogues of carbamyl aspartate as inhibitors of dihydroorotase: preparation of boronic acid transition-state analogues and a zinc chelator carbamylhomocysteine. J Med Chem 1990; 33(2):819-823.

58. Ames MM, Loprinzi CL, Collins JM., van Haelst-Pisani CM, Richardson RL, Rubin J, Moertel CG. Phase I and clinical pharmacologic evaluation of pirozantrone hydrochloride (oxantrazole). Cancer Res 1990; 50:3905-3909.

59. Loprinzi CL, Love RR, Garrity JA, Ames MM. Cyclophosphamide, methotrexate and 5-fluorouracil (CMS)-induced ocular toxicity. Cancer Invest 1990; 8:459-465.

60. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients. A Childrens Cancer Study Group Report. Cancer Res 1990; 50:6525-6528.

61. Mayeno AN, Lin F, Foote CS, Loegering DA, Ames MM, Hedberg CW, Gleich GJ. Characterization of "Peak E", a novel amino acid associated with Eosinophilia-Myalgia syndrome. Science 1990; 250:1707-1708.

62. Patel SR, Kvols LK, Rubin J, O'Connell MJ, Edmonson JH, Ames MM, Kovach JS. Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest. New Drugs 1991; 9:53-57.

63. Ames MM. Hexamethylmelamine: Pharmacology and mechanism of action. Cancer Treat Re 1991; 18 (Supplement A):3-14.

64. Ames MM, Mathiesen DA, Reid JM. Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat. Invest New Drugs 1991; 9:219-225.

65. Ames MM, Spreafico F. Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 1992; 6(Suppl 1):70-75.

66. Kuffel MJ, Reid JM, Ames MM. Anthracyclines and their c-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 1992; 30:51-57.

16 M.M. Ames, Ph.D.67. Reid JM, Mathiesen DA, Benson LM, Kuffel MJ, Ames MM. Murine pharmacokinetics

and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)-pyridine, NSC 338720]. Cancer Res 1992; 52:2830-2834.

68. Kinder DH, Elstad CA, Meadows GG, Ames MM. Antimetastatic activity of boro-amino acid analog protease inhibitors against B15Bl6 melanoma in vivo. Invasion and Metastasis 1992; 12:309-319.

69. Davis T, Miser AW, Loprinzi CL, Kaur JS, Burnham NL, Dose AM, Ames MM. Comparative morphine pharmacokinetics following sublingual, intramuscular and oral administration in patients with cancer. The Hospice J 1993; 9(1):85-90.

70. Zembower DE, Gilbert JA, Ames MM. Enantiospecific syntheses of -fluoromethyltryptophan analogues: interactions with tryptophan hydroxylase and aromatic-l-amino acid decarboxylase. J Med Chem 1993; 36:305-313.

71. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG. Pediatric Phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993; 53:1032-1036.

72. Benson LM, Tomlinson AJ, Reid JM, Walker DL, Ames MM, Naylor S. Study of in vivo pyrazoloacridine metabolism by capillary electrophoresis using isotachophoresis preconcentration in non-aqueous separation buffer. J High Resolution Chromatogr 1993; 16:324-326.

73. Tefferi A, Silverstein MN, Plumhoff EA, Reid JM, Ames MM. Suramin toxicity and efficacy in agnogenic myeloid metaplasia. J Natl Cancer Inst 1993; 85(18):1520-1522.

74. Tefferi A, Witzig TE, Reid JM, Li C-Y, Ames MM. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low- grade lymphoma. J Clin Oncol 1994; 12(3):569-574.

75. Walker DL, Reid JM, Ames MM. Preclinical pharmacology of Bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065. Cancer Chemother Pharmacol 1994; 34(4):317-322.

76. Zembower DE, Ames MM. Synthesis of 5-alkyl- and 5-aryl-L-tryptophan analogues via palladium-catalyzed cross-coupling of an iodinated cyclic tryptophan tautomer. Synthesis 1994; 12:1433-1436.

77. Dhodapkar MV, Richardson RL, Reid JM, Ames MM. Pyrazine diazohydroxide (NSC-361456): Phase I clinical and pharmacokinetic studies. Invest New Drugs 1994; 12:207-216.

78. Reid JM, Benson JW, Viallet J, Ames, MM. Preclinical pharmacology of cholera toxin (NSC 629801). Cancer Chemother Pharmacol 1995; 36(2):115-120.

17 M.M. Ames, Ph.D.79. Kuffel MJ, Ames MM. Comparative resistance of idarubicin, doxorubicin and their C-13

alcohol metabolites in human MDR1 transfected NIH-3T3 cells. Cancer Chemother Pharmacol 1995; 36(3):223-226.

80. Gilbert JA, Bates LA, Ames MM. Elevated aromatic-L-amino acid decarboxylase in human carcinoid tumors. Biochem Pharmacol 1995; 50(6):845-850.

81. Haddock MG, Ames MM, Bonner JA. Assessing the interaction of radiation with etoposide or idarubicin. Mayo Clin Proc 1995; 70:1-8.

82. Hartmann LC, Ames MM, Reid JM, Richardson RL. Phase I trial of diaziquone (AZQ) plus GM-CSF. Invest New Drugs 1995; 13:175-176.

83. Reid JM, Walker DL, Ames MM. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. Cancer Chemother Pharmacol 1996; 38:329-334.

84. Feig SA, Ames MM, Sather HN, Steinherz L, Reid JM, Trigg M, Pendergrass TW, Warkentin P, Gerber, M, Leonard M, Bleyer WA, Harris RE. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: A report from the Childrens Cancer Group. Med Ped Oncol 1996; 27:505-514.

85. Zembower DE, Neudauer CL, Wick MJ, Ames MM. Peptide Boronic Acids: Versatile synthetic ligands for affinity chromatography of serine proteinases. Inter J Peptide Protein Res 1996; 47(5):405-413.

86. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997; 3(7):1093-1100.

87. Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, Suman VJ, Marks RS, Erlichman C, Hartmann LC. Evaluation of continuous infusion suramin in metastatic breast cancer: Impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding factor proteins. Clin Cancer Res 1997; 3:1713-1720.

88. Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch TR. Phase I and pharmacologic trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor. Clin Cancer Res 1997; 3:2363-2370.

89. Reid JM, Stevens DC, Rubin J, Ames MM. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 1997; 3:2393-2398.

90. Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, Kaufmann SH. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res 1998; 4:117-130.

18 M.M. Ames, Ph.D.91. Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J,

Ames MM, Kaufmann SH. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res 1998; 4:683-691.

92. Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, Goldberg RM. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin Cancer Res 1998; 4:2111-2117.

93. Rajkumar SV, Buckner JC, Schomberg PJ, Reid JM, Bagniewski PJ, Ames MM, Cascino TL, Marks RS. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide and accelerated radiation therapy in patients with high-grade glioma. Int J Rad Oncol Biol Phys 1998; 42:969-975.

94. Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, Vezina LG, Ettinger, AG. Reaman GH. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children’s Cancer Group. J Clin Oncol 1998; 16(9):3037-3043.

95. Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM,

Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: A joint Children’s Cancer Group and Pediatric Oncology Branch Study. Blood 1998; 92(10):3569-3577.

96. Zembower DE, Zhang H, Lineswala JP, Kuffel MJ, Aytes SA, Ames MM. Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110. Bioorg Med Chem Lett 1999; 9:145-150.

97. Berg SL, Reid JM, Godwin K, Murry DJ, Poplack DG, Balis FM, Ames MM. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. J Ped Hematol Oncol 1999; 21(1):26-30.

98. Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WPY, Lim S, Figg WD. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 6209261) in patients with recurrent glioma. Mayo Clinic Proc 1999; 74:137-145.

99. Pitot HC, McElroy EA Jr, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski

PG, Walker DL., Rubin J, Goldberg RM, Adjei AA, Ames MM. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 1999; 5:525-531.

100. Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM: Metabolic activation of dacarbazine by human cytochromes P450: The role of the CYP1A1, CYP1A2 and CYP2E1. Clin Cancer Res 1999; 5:2192-2197.

101. Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM. Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. Biochem Pharmacol 1999; 58:1057-1066.

19 M.M. Ames, Ph.D.

102. Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DWW, Steinherz PG, Whitlock JA, Holcenberg JS. Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors. A report from the Children’s Cancer Group. Clin Cancer Res 1999; 5:3956-3962.

103. Budihardjo II, Boerner SA, Eckdahl S, Svingen PA, Rios R, Ames MM, Kaufmann SH. Effect of 6-Aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity. Mol Pharmacol 2000; 57:529-538.

104. Gilbert JA, Frederick LM, Ames MM. The Aromatic-L-Amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res 2000; 6:4365-4372.

105. Rajkumar SV, Reid JM, Novotny PJ. Safgren SL, Scheithauer BW, Johnson PS, Nair S, Morton RF, Hatfield AK, Krook JE, Ames MM, Buckner JC. A randomized Phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. J Neuro-Oncol 2000; 49:255-261.

106. Bracho F, Krailo MD, Shen V, Bergeron S, Davenport V, Liu-Mares W, Blazar BR, Panoskaltsis-Mortari A, van de Ven C, Secola R, Ames MM, Reid JM, Reaman GH, Cairo MS. A Phase I clinical, pharmacologic and biological trial of interleukin-6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: Enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin Cancer Res 2001; 7:58-67.

107. Galanis E, Goldberg R, Reid J, Atherton P, Sloan J, Pitot H, Rubin J, Adjei AA, Burch P, Safgren SL, Witzig TE, Ames MM, Erlichman C. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). Ann Oncol 2001; 12:701-707.

108. Safgren SL, Reid JM, Rios R, Ames MM. Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydrxoymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. J Chromatogr 2001; 754:91-96.

109. Wells RJ, Reid JM, Ames MM, Mares WL, Krailo MD, Seibel NL, Mosher R, Reaman GH, Wiersma SR. Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatric Hematol Oncol 2002; 24(2):89-93.

110. Pitot HC, Reid JM, Sloan JA, Ames MM, Adjei AA, Rubin J, Bagniewski PG, Atherton P, Rayson D, Goldberg RM, Erlichman C. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res 2002; 8(3):712-717.

111. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol 2002; 20(6):1683-1691.

20 M.M. Ames, Ph.D.

112. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharm 2002; 62:143-153.

113. Reid JM, Kuffel MJ, Ruben SL, Morales JJ, Rinehart KL, Squillace DP, Ames MM. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 2002; 8:2952-2962.

114. Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boerner SA, Atherton P, Ames MM, Kaufmann SH. A Phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest New Drugs 2002; 20:297-304.

115. Steinherz PG, Siebel NL, Ames MM, Avramis VI, Krailo MD, Liu-Mares W, Reid JM, Safgren SL, Reaman GH. Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): A report from the Children's Cancer Group. Leuk Lymphoma 2002; 43(10):1945-1950.

116. Reid JM, Squillace DP, Ames MM. Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice. Cancer Chemother Pharmacol 2003; 51:483-487.

117. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003; 14:1169-1176.

118. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil and leucovorin in patients with solid tumors. J Clin Oncol 2003; 21(20):3761-3769.

119. Reid JM, Walker DL, Miller JK, Benson LM, Tomlinson AJ, Naylor S, Blajeski AL, LoRusso PM, Ames MM. The metabolism of pyrazoloacridine (NSC 366140) by cytochromes P450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res 2004; 10:1471-1480.

120. Goetz MP, Ames MM, Weinshilboum RM. Primer on medical genomics Part XII: Pharmacogenomics--general principles with cancer as a model. Mayo Clinic Proc 2004; 79:376-384.

121. Reid JM, Qu W, Safgren SL, Ames MM, Krailo MD, Seibel NL, Kuttesch J, Holcenberg J. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 2004; 22(12):2445-2451 (2004).

122. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei, A, Croghan G, Erlichman C. Phase I trial of 17-allylamino-geldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23(6):1078-1087.

21 M.M. Ames, Ph.D.123. Gilbert JA, Frederick LM, Pobst LJ, Ames MM. Hydrogen peroxide degradation and

selective carbidopa-induced cytotoxicity against human tumor cell lines. Biochem Pharmacol 2005; 69:1159-1166.

124. Gilbert JA, Lloyd RV, Ames MM. Lack of Mutations in EGFR in Gastroenteropancreatic Neuroendocrine Tumors. (letter). N Engl J Med 2005; 353:209-210.

125. Bible KC, Lensing J.L, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK; Adjei AA, Erlichman C. Phase 1 trial of flavopiridol combined with cisplastin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11(16):5935-5941.

126. Kaufmann SK, Karp JE, Letendre L, Kottke TJ, Safgren S, Greeer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C. Phase I and Pharmacologic study of infusional tropotecan and carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res 2005; 11(18):6641-6649.

127. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18(10):1329-1335.

128. Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group Trial. Invest New Drugs 2005; 23(5):495-503.

129. Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: A children’s oncology group study. J Clin Oncol 2005; 23(36):9179-9186.

130. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23(36):9312-9318.

131. Johansen M, Kuttesch J, Bleyer WA, Krailo M, Ames M, Madden T. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: A report from the children’s oncology group. Clin Cancer Res 2006; 12(2):516-522.

132. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, Weinshilboum RM. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12(6):1794-1803.

133. Pobst LJ, Ames MM. CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines, Cancer Chemother Pharmacol 2006; 57(5)569-576.

22 M.M. Ames, Ph.D.134. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I

trial of oral fenretinide in children with high-risk solid tumors: A report from the Children’s Oncology Group (CCG 09709). J Clin Oncol 2006; 24(1):3423-3430.

135. Buhrow SA, Reid JM, Jia L, McGovern RM, Covey JM, Kobs DJ, Grossi IM, Ames MM. LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501). J Chromatogr B: Analyt Technol Biomed Life Sci 2006; 840(1 Special Issue SI):56-62.

136. Goetz MP, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch F, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: Data from the Italian tamoxifen trial - Reply. J Clin Oncol 2006; 24(22):3709.

137. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006; 12(20 Part 1):6087-6093.

138. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Barr Fritcher EG, Nibble AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.. Breast Cancer Res Treat 2007; 101(1):113-121.

139. Weigel BJ, Blaney SM, Reid JM, Safgren, SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames MM, Adamson PC. A Phase I study of 17-allylaminogeldanamycin (17-AAG) in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children’s Oncology Group Study. Clin Cancer Res 2007;13(6):1789-93.

140. Le SB, Hailer MK, Buhrow S, Wang Q, Flatten K, Pediaditakis P, Bible KC, Lewis LD, Sausville EA, Pang Y-P, Ames MM, Lemasters JJ, Holmuhanedov EL, Kaufmann SH. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem 2007; 282(12):8860-8872.

141. Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey L, Nuchtern J, Dauser R, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol 2007; 59(4):461-466.

142. Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol 2007; 25(12):1505-1511.

143. McWilliams RR, Goetz MP, Morlan BW, Salim M, Rowland KM, Krook JE, Ames MM, Erlichman C. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6(7):516-521.

23 M.M. Ames, Ph.D.144. Alberts SR, Kim GP, Mahoney MR, Gornet MK, Rubin J, Ames M, Goetz MP,

Weinshilboum RM, Nicol SJ, Goldberg RM. Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248. Clin Colorectal Cancer 2007; 6(8):572-577.

145. Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JM, Ames MM, Adjei AA.Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res 2007; 67(18):8772-8782.

146. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid JM, Federspiel M, Ames MM, Dingli D, Schweikart K, Welch A, Dispenzieri A, Peng K-W, Russell SJ. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007; 82(6):700-710. PMCID: 2769566

147. Furth AF, Mandrekar SJ, Tan AD, Rau A, Felten SJ, Ames MM, Adjei AA, Reid JM, Erlichman C. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomucin. Cancer Chemother Pharmacol 2008; 61:39-45. PMCID: in process

148. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008; 83(1):160-166. PMCID:2752373..

149. Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA, Reid JM, Ames MM, Munn DH. Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol 2008; 46(1):203-211. PMCID:2744343.

150. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 2008; 68(6):1970-1978. PMCID: in process

151. Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev 2008; 17(3):674-679. PMCID:2435402.

152. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL. A phase I and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a children’s oncology group study. Pediatr Blood Cancer 2008; 50(4):788-792. PMCID: in process

153. Patra CR, Cao S, Safgren S, Bhattacharya R, Ames MM, Shah V, Reid JM, Mukherjee P. Intracellular fate of a targeted delivery system. Journal Biomed Nanotech 2008; 4(4):508-14. PMCID: in process

24 M.M. Ames, Ph.D.154. Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE,

Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MM. Moleular analysis of metaplastic breast carcinoma: high EGFR copy numbr via aneusomy. Mol Cancer Ther 2008; 7(4):944-951. PMCID:25745608

155. Gálvez-Peralta M, Dai NT, Loegering DA, Flatten KS, Safgren SL, Wagner JM, Ames MM, Karnitz LM, Kaufmann SH. Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines. Mol Pharmacol. 2008 Sep; 74(3):724-35. PMCID:2574763.

156. Kocabas NA, Aksoy P, Pelleymounter LL, Moon I, Ryu JS, Gilbert JA, Salavaggione OE, Eckloff BW, Wieben ED, Yee V, Weinshilboum RM, Ames MM. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos. 2008 Sep; 36(9):1951-9. PMCID: 3066084

157. Li L, Fridley B, Kalari K, Jenkins G, Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D, Wang L. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res 2008 Sept; 68(17):7050-58. PMCID:2562356.

158. Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma X-J, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: Combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 2008; 14(18):5864-5868. PMCID:2596658

159. Bradley KA, Pollack IF, Reid JM, Adamson PC, Ames MM, Vezina G, Blaney S, Ivy P, Zhou T, Krailo M, Reaman G, Mehta MP; Children's Oncology Group. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol. 2008 Oct; 10(5):752-8. PMCID: 2666252

160. Goetz MP, Ames MM, Weinshilboum M, Ingle JN. Endocrine therapy in 2009: consideration of the tumor and the host. Oncology (Williston Park). 2009 Feb; 23(2):150-1, 154. PMCID: in process

161. Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E; North Central Cancer Treatment Group. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol. 2009 Apr; 92(2):165-75. PMCID:2721337

162. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC. Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol. 2009 Apr; 27(12):2052-58. PMCID:2669764

25 M.M. Ames, Ph.D.163. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon

W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009 Oct 7; 302(13):1429-36.

164. Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann SH. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant 2010 Mar, 45(3):490-97. PMCID: PMC2836387

165. Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr., Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children’s Oncology Group Phase I consortium study. Pediatr Blood Cancer 2010 Apr; 54(4):538-45. PMCID: 3074342

166. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP. Co-prescription of Tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 2010; 28(16):2768-76. PMCID: PMC2881853.

167. Reinicke KE, Kuffel MJ, Goetz MP, Ames MM. Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells. Can Chemother Pharmacol. 2010; 66(3):575-83. PMCID: PMC2931270

168. Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC. Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. J Neurooncol 2010 Aug; 99:73-80. PMCID: 2897141

169. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. J Clin Oncol. 2010 Aug 1; 28(22):3623-29. PMCID: PMC2917318

170. Gilbert JA, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, CArboni JM, Gottardis MM Ames MM. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endo Relat Cancer. 2010 Sept; 17(3):623-36. Epub 2010 Jun 25. PMCID in process.

171. Beumer JH, Eiserman JL, Gilbert JA, HOlleran JL, Yellow-Duke AE, Clausen DM, D’Argenio DZ, Ames MM, Hersberger PA, Parise RA, Bai L, Covey JM, Egorin MJ.Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemother Pharmacol.. 2011 Feb; 67:421-30. Epub 2010 May 5. PMCID: PMC2954253

26 M.M. Ames, Ph.D.172. Rudin D, Li L, Niu N, Kalari KR, Gilbert JA, Ames MM, Wang L. Gemcitabine

Cytoxicity: Interaction of Efflux and Deamination. J Drug Metab Toxicol. 2011 Feb 2; 2(107)1-10. PMCID: 3144579

173. Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ. Cancer Prevention Network. Phase 0 clinical chemoprevention trial of the Akt inhibitor SSR13668. Cancer Prev Res (Phila). 2011 Mar; 4(3):347-53. PMCID: 3061470

174. Reid JM, Buhrow SA, Kuffel MJ, Jia L, Spanswick VJ, Hartley JA, Thurston DE, Tomaszewski JE, Ames MM. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rates. Cancer Chemother Pharmacol. 2011 Sept; 68(3):777-86. PMCID in process

175. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH. Phase I study of PARP inhibitor ABT-888 in combinatgion with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011 Sept 1; 71(17):5626-34.PMCID: 3166628

176. Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A Phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Invest New Drugs 2011 Oct; 29(5):1004-12. PMCID in process

177. Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Phase I and pharmacological sstudy of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 2011 Nov; 96(11):1619-26. PMCID: 3208679

178. Moyer AM, Suman VJ, Weinshilboum RM, Avula R, Black JL, Safgren SL, Kuffel MJ, Ames MM, Ingle JN, Goetz MP. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics. 2011 Nov; 12:1535-43.PMCID in process

179. Goetz MP, Schaid DJ, Wickerham DL, Safgren S, Mushiroda T, Kubo M, Batzler A, Costantino JP, Vogel VG, Paik S, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM, Ingle JN, Ames MM. Evaluation of CYP2D6 and efficacy of Tamoxifen and Raloxifene in women treated for breast cancer chemoprevention: Results from the NSABP P1 and P2 Clinical Trials. Clin Cancer Res. 2011 Nov 1; 17:6944-51. PMCID: 3207003

180. Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/Fenretinide) in pediatric patients with refractory or

27 M.M. Ames, Ph.D.recurrent neuroblastoma: A report from the Children’s Oncology Group. Clin Cancer Res. 2011 Nov 1; 17(21):6858-66. PMCID: 3207022

181. Zembower DE, Xie Y, Koohang A, Kuffel MJ, Ames MM, Zhou Y, Mishra R, Mar AA, Flavin MT, Xu ZQ. Methylenedioxy- and Ethylenedioxy-Fused Indolocarbazoles. Potent Human Topoisomerase I Inhibitors and Antitumor Agents. Anticancer Agents Med Chem. 2012 Nov 1; 12(9):1117-31.

182. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 1; 18(21):6032-9.

183. Warwick AB, Malempati S, Krailo M, Melemed A, Gorlick R, Ames MM, Safgren SL, Adamson PC, Blaney SM. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children’s Oncology Group Study. Pediat Blood Cancer, 2013; 60(2):237-41.

184. Holtan SG, Steen PD, Foster NR, Erlichman C, Medeiros F, Ames MM, Safgren SL, Graham DL, Behrens RJ, Goetz MP. Gemcitabine and Irinotecan as first-line therapy for carcinoma of unkown primary: results of a multicenter Phase II trial. PLoS One 2012:7(7):e39285. Epub 2012 Jul 17. PMCID:PMC3398897

185. Holtan SG, Steen PD, Foster NR, Erlichman C, Medeiros F, Ames MM, Safgren SL, Graham DL, Behrens RJ, Goetz MP. Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial. PLoS One. 2012; 7(7):e39285.

186. Warwick AB, Malempati S, Krailo M, Melemed A, Gorlick R, Ames MM, Safgren SL, Adamson PC, Blaney SM. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer. 2013; 60(2):237-41.

187. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, Mcgovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study. Pediatr Blood Cancer. 2013; 60(9):1452-7.

188. Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN. CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8. Clin Cancer Res. 2013 Jan 15; 19(2):500-7.

189. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid

28 M.M. Ames, Ph.D.tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013 Mar; 60(3):390-5.

190. Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs. 2013 Mar 31.

191. Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM, Cancer Prevention Network. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. J Clin Pharmacol. 2013 Apr; 53(4):403-12.

192. Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, Ames MM. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas. 2013 Apr; 42(3):411-21.

193. Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res. 2013 Apr 1; 19(7):1873-83.

194. Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, Zhang L, Thorland EC, Minn KT, Tentu R, Eckloff BW, Wieben ED, Wu Y, Cunningham JM, Nagorney DM, Gilbert JA, Ames MM, Beutler AS. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest. 2013 Jun 3; 123(6):2502-8.

195. Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, Kubo M, Costantino JP, Vogel VG, Paik S, Goetz MP, Ames MM, Jenkins GD, Batzler A, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM. Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. Cancer Discov. 2013 Jul; 3(7):812-25.

196. Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Dec; 31(6):1539-46.

197. Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs. 2013 Dec; 31(6):1559-67.

29 M.M. Ames, Ph.D.198. Province MA, Goetz MP, Brauch H, Flockhart DA,

Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonne AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE. CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations. Clin Pharmacol Ther. 2014 Feb; 95(2):216-27.

199. Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs. 2014 Jan; 32(2); 323-29.

200. Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone and acetaminophen: a case report from a New Approaches to Neiuroblastoma (NANT) Phase I study. BMC Research Notes. 2014 Jul; 7(1); 256.

201. Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JM, Mcgovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM. A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study. Pediatr Blood Cancer. 2014 Jun; 61(7):1246-51.

202. Reid JM, Buhrow SA, Gilbert JA, Jia L, Shoji M, Snyder JP, Ames MM. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC716993). Cancer Chemother Pharmacol. 2014 Jun; 73(6); 1137-1146.

203. Reid JM, Goetz MP, Buhrow SA, Walden C, Safgren SL, Kuffel MJ, Reinicke KE, Suman V, Haluska P, Hou X, Ames MM. Pharmacokinetics of endoxifen and tamoxifen in female mice: Implications for comparative in vivo activity studies. Cancer Chemother Pharmacol. 2014; in press.

204. Goetz M, Sun J, Suman V, Silva G, Perou C, Nakamura Y, Cox N, Stephens P, Miller V, Ross J, Chen D, Safgren S, Kuffel M, Ames M, Gomez H, Gonzalez-Angulo A, Burgues O, Brauch H, Ingle J, Ratain M, Yelensky. Loss of heterozygosity at the CYP2D6 locus in breast cancer; Implications for germline pharmacogenetic studies. J Natl Can Institute. 2014; in press.

Books

30 M.M. Ames, Ph.D.1. Ames MM, Powis G, Kovach JS. Pharmacokinetics of anticancer agents in human.

Amsterdam: Elsevier; 1983. 479 p.

2. Grochow LB, Ames MM. A Clinician’s Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Baltimore: Williams & Wilkins; 1998. 578 p.

Book Chapters:

1. Castagnoli N Jr, Melmon KL, Freed CR, Ames MM, Kalir A, Weinkman R. Application of chemical ionisation mass spectrometry and stable isotopes in studies of a-methyldopa metabolism. In: Baillie TA, editor. Proceedings of the Symposium on Stable Isotopes: Application in Pharmacology, Toxicology and Clinical Research. Baltimore: University Park Press, 1977, pp. 261-279.

2. Lovenberg W, Ames MM, Lerner P. Regulation of tyrosine hydroxylase activity. In: Costa E, Gessa GL, Editors. Advances in Biochemical Psychopharmacology. New York: Raven Press, 1977, Volume 16, pp. 461-464.

3. Lovenberg W, Ames MM, Lerner P. Mechanism of Short-term Regulation in Tyrosine Hydroxylase. In: Lipton MA, DiMascio A, Killam KF, Editors. Psychopharmacology: A Generation of Progress. New York: Raven Press, 1978, pp. 247-259.

4. Lieber MM, Ames MM, Powis G, Kovach JS. Drug sensitivity testing in vitro with a liver microsome "activated" soft agar human stem cell colony assay. In: Fidler IJ, White RJ, Editors. Design of Models for Testing Cancer Therapeutic Agents. New York: Van Nostrand Reinhold Company, 1982, pp. 12-18.

5. Powis G, Ames MM, Kovach JS. Dose-dependent pharmacokinetics of anticancer drugs. In: Ames MM, Powis G, Kovach JS, Editors. Pharmacokinetics of Anticancer Agents in Humans. Netherlands: Elsevier Science Publishers B.V., 1983, pp. 49-75.

6. Ames MM, Powis G. Pharmacokinetics of nitrosoureas. In: Ames MM, Powis G, Kovach JS, Editors. Pharmacokinetics of Anticancer Agents in Humans. Netherlands: Elsevier Science Publishers B.V., 1983, pp. 113-134.

7. Ames MM. Pharmacokinetics of antitumor agents in children. In: Ames MM, Powis G, Kovach JS, Editors. Pharmacokinetics of Anticancer Agents in Humans. Netherlands: Elsevier Science Publishers B.V., 1983, pp. 399-431.

8. Ames MM. Metabolism of anticancer drugs in development. In: Powis G, Prough RA, Editors. Metabolism and Action of Anti-Cancer Drugs London: Taylor and Francis, 1987, pp. 296-323.

9. Reid JM, Ames MM. Assay methodology. In: Grochow LB, Ames MM, Editors. A Clinician’s Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Baltimore: Williams & Wilkins, 1998, pp. 497-514.

Abstracts: Not listed (>200)

31 M.M. Ames, Ph.D.